Rilonacept
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scleroderma
Conditions
Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
Trial Timeline
Dec 1, 2011 → Aug 11, 2017
NCT ID
NCT01538719About Rilonacept
Rilonacept is a phase 1/2 stage product being developed by Regeneron Pharmaceuticals for Scleroderma. The current trial status is completed. This product is registered under clinical trial identifier NCT01538719. Target conditions include Scleroderma, Systemic Sclerosis, Diffuse Scleroderma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00609544 | Phase 2 | Withdrawn |
| NCT02828033 | Phase 1 | UNKNOWN |
| NCT01538719 | Phase 1/2 | Completed |
| NCT00856206 | Phase 3 | Completed |
| NCT00610363 | Phase 2 | Completed |
Competing Products
15 competing products in Scleroderma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Cuprimine (penicillamine) | Merck | Pre-clinical | 23 |
| rapcabtagene autoleucel + rituximab | Novartis | Phase 2 | 52 |
| STI571 | Novartis | Phase 2 | 52 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Mycophenolate mofetil | Roche | Pre-clinical | 23 |
| Mycophenolate mofetil + Cyclophosphamide + Placebo | Roche | Phase 2 | 52 |
| Fludarabine + Cyclophosphamide + Thymoglobulin | Amgen | Phase 1 | 32 |
| BMS-986020 | Bristol Myers Squibb | Phase 2 | 51 |
| dasatinib | Bristol Myers Squibb | Phase 1/2 | 40 |
| Abatacept + Placebo | Bristol Myers Squibb | Phase 1/2 | 40 |
| AVID200 | Bristol Myers Squibb | Phase 1 | 32 |
| Riociguat + Placebo | Bayer | Phase 2 | 49 |
| Riociguat (Adempas, BAY63-2521) + Placebo | Bayer | Phase 2 | 49 |